RELIEF THERAPEUTICS HOLDING AG

(RLF)
  Report
Delayed Swiss Exchange  -  11:30 2022-06-24 am EDT
0.0293 CHF   +3.17%
06/21Acer Therapeutics Shares Hit 52-Week Low After FDA Rejects ACER-001
DJ
06/21Relief Therapeutics, Acer's New Drug Application For Urea Cycle Disorders Drug Rejected by US FDA; Shares Sink 9%
MT
06/21ACER THERAPEUTICS : FDA Rejects ACER-001 Application
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Relief Therapeutics to Participate in Industry and Investor Conferences in May

05/09/2022 | 01:02am EDT

Relief Therapeutics Holding SA / Key word(s): Conference
Relief Therapeutics to Participate in Industry and Investor Conferences in May

09.05.2022 / 07:00


Relief Therapeutics to Participate in Industry and Investor Conferences in May

Geneva, Switzerland, May 9, 2022 ? RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (?Relief?), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, today announced participation in the following industry and investor conferences in May.

- May 16-18 (in-person)/May 23-24 (virtual partnering): Bio?quity Europe 2022. Jack Weinstein, Chief Financial Officer and Treasurer of Relief will present a company overview on May 17 at 2:30 p.m. CEST, in Milan, Italy. The Bio?quity Europe one-on-one partnering platform enables partners and investors to schedule virtual meetings. Interested parties can register at: https://informaconnect.com/bioequity-europe/registration-options/.

- May 23-26: H.C. Wainwright Global Investment Conference. Mr. Weinstein will present a company overview at the conference on Tuesday, May 24 at 12:00 p.m. EDT. Management will host one-one-one meetings during the conference. Institutional investors who are registered for the event can log into www.hcwevents.com to request a meeting with the company. An audio webcast of the presentation will be available on the Relief website at: https://www.relieftherapeutics.com/news-and-events and will be archived for a period of 90 days after the conference.

ABOUT RELIEF

Relief focuses primarily on clinical-stage programs based on molecules with a history of clinical testing and use in human patients or a strong scientific rationale. Relief?s drug candidate, RLF-100® (aviptadil), a synthetic form of Vasoactive Intestinal Peptide (VIP), is in late-stage clinical testing in the U.S. for the treatment of respiratory deficiency due to COVID-19 through Relief?s collaboration partner in the U.S., NeuroRx, Inc. Relief also has a Collaboration and License Agreement with Acer Therapeutics for the worldwide development and commercialization of ACER-001 (sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including Urea Cycle Disorders and Maple Syrup Urine Disease. Acer?s new drug application for ACER-001 for use as a treatment of urea cycle disorders was recently accepted by the FDA for filing with a PDUFA decision date of June 5, 2022. Finally, Relief's acquisitions last summer of APR Applied Pharma Research SA and AdVita Lifescience GmbH brought to Relief a diverse pipeline of marketed and development-stage programs.

RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbol RLFTF. For more information, visit www.relieftherapeutics.com. Follow us on LinkedIn.


CONTACT:
RELIEF THERAPEUTICS Holding SA

Jack Weinstein
Chief Financial Officer and Treasurer
contact@relieftherapeutics.com

FOR MEDIA/INVESTOR INQUIRIES:
Rx Communications Group

Michael Miller
+1-917-633-6086
mmiller@rxir.com
 

Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding SA. Such statements involve certain known and unknown risks, uncertainties and other factors, including those risks discussed in RELIEF THERAPEUTICS Holding SA's press releases and filings with the SIX and with the U.S. Securities and Exchange Commission, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.



End of Media Release


Language: English
Company: Relief Therapeutics Holding SA
Avenue de Secheron 15
1202 Geneva
Switzerland
Phone: +41 22 545 11 16
E-mail: contact@relieftherapeutics.com
Internet: https://relieftherapeutics.com
ISIN: CH0100191136
Valor: 10019113
Listed: SIX Swiss Exchange
EQS News ID: 1345297

 
End of News EQS News Service

1345297  09.05.2022 

fncls.ssp?fn=show_t_gif&application_id=1345297&application_name=news&site_id=zonebourse_sftp

© EQS 2022
All news about RELIEF THERAPEUTICS HOLDING AG
06/21Acer Therapeutics Shares Hit 52-Week Low After FDA Rejects ACER-001
DJ
06/21Relief Therapeutics, Acer's New Drug Application For Urea Cycle Disorders Drug Rejected..
MT
06/21ACER THERAPEUTICS : FDA Rejects ACER-001 Application
DJ
06/21Acer Therapeutics and Relief Therapeutics Announce Update on U.S. FDA Review of New Dru..
EQ
06/21Acer Therapeutics and Relief Therapeutics Announce Update on U.S. FDA Review of New Dru..
AQ
06/21Acer Therapeutics and Relief Therapeutics Announce Update on U.S. FDA Review of New Dru..
CI
06/17Relief Therapeutics Files Amendment No. 3 to its Registration Statement on Form 20-F wi..
EQ
06/13US FDA Rejects Relief Therapeutics Partner NRx's Breakthrough Request For Zyesami
MT
06/13Relief Reports that its U.S. Collaboration Partner has Announced an Update on Breakthro..
EQ
06/08Relief Therapeutics' Collaboration Partner Acer Therapeutics Awaits US FDA Nod On Urea ..
MT
More news
Financials
Sales 2022 20,0 M 20,9 M 20,9 M
Net income 2022 - - -
Net Debt 2022 - - -
P/E ratio 2022 -
Yield 2022 -
Capitalization 121 M 126 M 126 M
Capi. / Sales 2022 6,03x
Capi. / Sales 2023 1,26x
Nbr of Employees 10
Free-Float 62,7%
Chart RELIEF THERAPEUTICS HOLDING AG
Duration : Period :
Relief Therapeutics Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RELIEF THERAPEUTICS HOLDING AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 0
Last Close Price 0,03 CHF
Average target price 0,41 CHF
Spread / Average Target 1 282%
Managers and Directors
Jack M. Weinstein Chief Financial Officer & Treasurer
Raghuram Selvaraju Chairman
Nermeen Varawalla Chief Medical Officer
Taneli Jouhikainen Chief Operating Officer
Thomas Plitz Director
Sector and Competitors
1st jan.Capi. (M$)
RELIEF THERAPEUTICS HOLDING AG-52.89%126
MODERNA, INC.-43.20%57 385
IQVIA HOLDINGS INC.-24.22%40 468
LONZA GROUP AG-32.67%39 851
SEAGEN INC.16.00%33 010
CELLTRION, INC.-13.38%18 371